| Johnson
Matthey's Biomedical Materials business has received
manufacturing registrations from the US Drug Enforcement
Administration (DEA) for a broad range of controlled
drug active ingredients and raw materials. These products
include dihydrocodeine, diphenoxylate, hydrocodone,
levorphanol, methadone, oxycodone, oxymorphone and
thebaine. They are used in a range of pharmaceutical
applications, primarily in pain management. There are
well established markets for these materials in the
US, which include many generic drug manufacturers.
The total available US market for these products is
worth approximately $ 70 million per annum.
Commenting on the DEA registrations,
Dr Mike Cleare, Managing Director with responsibility for the
Biomedical Materials business, said:
"Pharmaceutical Materials represent
an important growth opportunity for Johnson Matthey. We expect
that the development and commercialisation of new products such
as these, along with our strong technical capabilities and commitment
to customer service, will continue to drive the rapid expansion
of the important controlled substances segment of our business."
Johnson Matthey's Biomedical
Materials business, located in West Deptford, New Jersey, USA,
manufactures and markets a broad range of active pharmaceutical
ingredients including methylphenidate, fentanyl and other controlled
drug products as well as the important anti-cancer drugs, cisplatin
and carboplatin.
|
Enquiries:
Johnson
Matthey
Ian Godwin
Group Public Relations Manager
+44 (0)171 269 8410
|
